On its (i) Disinvestment of ‘Horlicks’ and other Consumer Healthcare nutrition products in India to Unilever, including the merger of its Indian listed entity, GlaxoSmithKline Consumer Healthcare Limited with Hindustan Unilever Limited and subsequent sale of approximately 5.69% stake of HUL on the floor of the stock exchange, the largest secondary trade on Indian stock exchanges, awarded ‘Deal of the Year’ by IBLJ (2019) & (2020) respectively (ii) Separation of its pharmaceutical and consumer healthcare business, which involved setting up a joint venture arrangement with Pfizer Inc. for the consumer healthcare business ‘Haleon’
